The struggle to maintain weight loss after GLP-1 therapy highlights a critical gap in obesity treatment—the need for interventions that create lasting metabolic changes rather than temporary appetite suppression. A novel compound targeting fat storage machinery may offer a fundamentally different approach to sustainable weight management.
Researchers identified VB-85387 as a highly selective inhibitor of human MOGAT2, an enzyme crucial for triglyceride synthesis in the intestine and liver. When administered to diet-induced obese mice for seven days, the compound triggered significant weight reduction alongside decreased food intake and improved glucose tolerance. The treatment elevated β-hydroxybutyrate levels, indicating enhanced fat burning, while simultaneously reducing liver triglyceride accumulation and increasing natural GLP-1 production.
The metabolic profile suggests VB-85387 activates a coordinated fat-burning program typically seen during fasting or ketogenic states. Gene expression analysis revealed increased PPARα-dependent fatty acid oxidation pathways and suppressed SREBP-mediated fat synthesis genes, indicating the compound shifts cellular metabolism from storage to utilization mode.
This represents a promising alternative to current obesity treatments that primarily work through appetite suppression. MOGAT2 inhibition appears to address weight gain at the metabolic level by preventing dietary fat absorption and simultaneously promoting stored fat breakdown. However, the seven-day treatment window leaves critical questions about long-term efficacy and safety unanswered. The compound's selectivity for human MOGAT2 suggests potential for clinical translation, though extensive optimization will be needed to develop a therapeutically viable drug candidate.